{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:13:34Z","timestamp":1788866014260,"version":"build-2803163510"},"reference-count":92,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173177, 82472955, 82103429"],"award-info":[{"award-number":["82173177, 82472955, 82103429"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Malignant brain tumors have high morbidity and poor prognosis. Prostate-specific membrane antigen (PSMA) has emerged as a promising vascular biomarker in this setting, particularly in gliomas and brain metastases. This review synthesizes current evidence on PSMA expression patterns, regulatory mechanisms, imaging applications, and translational potential in malignant brain tumors. Across studies, PSMA expression in gliomas is predominantly localized to tumor-associated neovasculature and closely associated with angiogenic signaling. In brain metastases, PSMA expression appears more heterogeneous and more strongly influenced by metastatic origin and the brain microenvironment. These biological features provide a rationale for PSMA-targeted positron emission tomography, which offers high lesion-to-background contrast. Clinically, PSMA-targeted imaging shows promise for glioma grading, selected post-treatment assessment, and detection of brain metastases across multiple primary tumors. However, therapeutic translation remains limited because compartment-specific target distribution, inconsistent target retention, delivery barriers, and uncertain dosimetry continue to constrain the efficacy of PSMA-targeted treatment strategies in malignant brain tumors. Current evidence supports PSMA as a promising complementary imaging biomarker rather than as a validated therapeutic target in malignant brain tumors. Future progress will require standardized detection methods, stronger mechanistic validation, and dosimetry-guided clinical development.<\/jats:p>","DOI":"10.3389\/fonc.2026.1934007","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:05:36Z","timestamp":1788865536000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prostate-specific membrane antigen in malignant brain tumors: vascular heterogeneity, imaging promise, and therapeutic challenges"],"prefix":"10.3389","volume":"16","author":[{"given":"Bihani","family":"Pokharel","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Fudan University Shanghai Cancer Center","place":["Shanghai, China"]},{"name":"Department of Oncology, Shanghai Medical College, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingtao","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Fudan University Shanghai Cancer Center","place":["Shanghai, China"]},{"name":"Department of Oncology, Shanghai Medical College, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuechao","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Fudan University Shanghai Cancer Center","place":["Shanghai, China"]},{"name":"Department of Oncology, Shanghai Medical College, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Fudan University Shanghai Cancer Center","place":["Shanghai, China"]},{"name":"Department of Oncology, Shanghai Medical College, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina Shah","family":"Kazmi","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Fudan University Shanghai Cancer Center","place":["Shanghai, China"]},{"name":"Department of Oncology, Shanghai Medical College, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqun","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Fudan University Shanghai Cancer Center","place":["Shanghai, China"]},{"name":"Department of Oncology, Shanghai Medical College, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangdong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Fudan University Shanghai Cancer Center","place":["Shanghai, China"]},{"name":"Department of Oncology, Shanghai Medical College, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Fudan University Shanghai Cancer Center","place":["Shanghai, China"]},{"name":"Department of Oncology, Shanghai Medical College, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noaf194","article-title":"CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2018-2022","volume":"27","author":"Price","year":"2025","journal-title":"Neuro Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro-Oncology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40001-023-01011-y","article-title":"The global prevalence of primary central nervous system tumors: a systematic review and meta-analysis","volume":"28","author":"Salari","year":"2023","journal-title":"Eur J Med Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14102412","article-title":"Epidemiology of glioblastoma multiforme-literature review","volume":"14","author":"Grochans","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17010146","article-title":"Glioblastoma: Clinical presentation, multidisciplinary management, and long-term outcomes","volume":"17","author":"Sipos","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab101","article-title":"Epidemiology of brain metastases and leptomeningeal disease","volume":"23","author":"Lamba","year":"2021","journal-title":"Neuro-Oncology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-018-0055-y","article-title":"Brain metastases","volume":"5","author":"Achrol","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2008-0272","article-title":"Angiogenesis as a therapeutic target in Malignant gliomas","volume":"14","author":"Chi","year":"2009","journal-title":"Oncologist"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines14010119","article-title":"Mechanisms, imaging phenotypes, and therapeutic advances of neovascularization in brain metastases","volume":"14","author":"Liu","year":"2026","journal-title":"Biomedicines"},{"key":"B10","article-title":"Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigeni","volume":"53","author":"Israeli","year":"1993","journal-title":"Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.2.749","article-title":"Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase","volume":"93","author":"Carter","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"B12","article-title":"Prostate-specific membrane antigen expression in normal and Malignant human tissues","volume":"3","author":"Silver","year":"1997","journal-title":"Clin Cancer Res"},{"key":"B13","article-title":"Expression of the prostate-specific membrane antigen","volume":"54","author":"Israeli","year":"1994","journal-title":"Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30080529","article-title":"PSMA targeted molecular imaging and radioligand therapy for prostate cancer: Optimal patient and treatment issues","volume":"30","author":"Hoshi","year":"2023","journal-title":"Curr Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2025.06.006","article-title":"PSMA-targeted positron emission tomography imaging in solid tumors other than prostate carcinoma: An update","volume":"55","author":"Nyakale","year":"2025","journal-title":"Semin Nucl Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17071239","article-title":"Evaluating the potential of PSMA targeting in CNS tumors: Insights from large-scale transcriptome profiling","volume":"17","author":"Kraya","year":"2025","journal-title":"Cancers"},{"key":"B17","article-title":"Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature","volume":"59","author":"Chang","year":"1999","journal-title":"Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2010-0740-OA","article-title":"Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme","volume":"135","author":"Wernicke","year":"2011","journal-title":"Arch Pathol Lab Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05433-w","article-title":"PSMA radioligand therapy for solid tumors other than prostate cancer: Background, opportunities, challenges, and first clinical reports","volume":"48","author":"Uijen","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B20","article-title":"Prostate-specific membrane antigen is produced in tumor-associated neovasculature","volume":"5","author":"Chang","year":"1999","journal-title":"Clin Cancer Res"},{"key":"B21","article-title":"Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium","volume":"57","author":"Liu","year":"1997","journal-title":"Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11070624","article-title":"PSMA expression in 122 treatment naive glioma patients related to tumor metabolism in 11C-methionine PET and survival","volume":"11","author":"Traub-Weidinger","year":"2021","journal-title":"J Pers Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4103\/abr.abr_209_18","article-title":"Prostate-specific membrane antigen expression in neovasculature of glioblastoma multiforme","volume":"8","author":"Mahzouni","year":"2019","journal-title":"Adv BioMed Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000002520","article-title":"Differential uptake of 68Ga-PSMA-HBED-CC (PSMA-11) in low-grade versus high-grade gliomas in treatment-naive patients","volume":"44","author":"Verma","year":"2019","journal-title":"Clin Nucl Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000004903","article-title":"68Ga-PSMA-11 PET\/CT imaging in brain gliomas and its correlation with clinicopathological prognostic parameters","volume":"48","author":"Verma","year":"2023","journal-title":"Clin Nucl Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000002821","article-title":"18F-PSMA 1007 uptake in brain metastases from breast cancer","volume":"45","author":"Marafi","year":"2020","journal-title":"Clin Nucl Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nucmedbio.2021.02.003","article-title":"[99mTc]Tc-iPSMA SPECT brain imaging as a potential specific diagnosis of metastatic brain tumors and high-grade gliomas","author":"Vallejo-Armenta","year":"2021","journal-title":"Nucl Med Biol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000001769","article-title":"Prostate-specific membrane antigen\u2013targeted imaging with [18F]DCFPyL in high-grade gliomas","volume":"42","author":"Salas Fragomeni","year":"2017","journal-title":"Clin Nucl Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-018-2825-5","article-title":"Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with 89Zr-Df-IAB2M anti-PSMA minibody","volume":"138","author":"Matsuda","year":"2018","journal-title":"J Neuro-Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265738","article-title":"PET imaging and protein expression of prostate-specific membrane antigen in glioblastoma: A multicenter inventory study","volume":"64","author":"Van Lith","year":"2023","journal-title":"J Nucl Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07338-4","article-title":"PSMA radioligand uptake correlates with PSMA expression in high-grade glioma and brain metastasis: Insights from a prospective PET-MRI guided multiregional biopsy study","volume":"52","author":"Pruis","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11041148","article-title":"PSMA expression correlates with improved overall survival and VEGF expression in glioblastoma","volume":"11","author":"Yuile","year":"2023","journal-title":"Biomedicines"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.646387","article-title":"PSMA expression in glioblastoma as a basis for theranostic approaches: A retrospective, correlational panel study including immunohistochemistry, clinical parameters and PET imaging","volume":"11","author":"Holzgreve","year":"2021","journal-title":"Front Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.31557\/APJCP.2023.24.5.1797","article-title":"Prostate-specific membrane antigen (PSMA) expression in the neovasculature of high grade gliomas (histopathological and immunohistochemical study)","volume":"24","author":"Abdel Maguid","year":"2023","journal-title":"Asian Pac J Cancer Prev"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3724\/abbs.2022157","article-title":"Secreted phosphoprotein 1 promotes angiogenesis of glioblastoma through upregulating PSMA expression via transcription factor HIF1\u03b1","volume":"55","author":"Tu","year":"2022","journal-title":"ABBS"},{"key":"B36","doi-asserted-by":"crossref","first-page":"45","DOI":"10.30699\/ijp.13.1.45","article-title":"Expression of prostate-specific membrane antigen (PSMA) in brain glioma and its correlation with tumor grade","volume":"13","author":"Saffar","year":"2018","journal-title":"Iran J Pathol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.598377","article-title":"Prostate-specific membrane antigen (PSMA) promotes angiogenesis of glioblastoma through interacting with ITGB4 and regulating NF-\u03baB signaling pathway","volume":"9","author":"Gao","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00084-06","article-title":"Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction","volume":"26","author":"Conway","year":"2006","journal-title":"Mol Cell Biol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000005365","article-title":"Prostate-specific membrane antigen use in glioma management: Past, present, and future","volume":"49","author":"McBriar","year":"2024","journal-title":"Clin Nucl Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12071665","article-title":"Diagnostic accuracy of PET\/CT or PET\/MRI using PSMA-targeting radiopharmaceuticals in high-grade gliomas: A systematic review and a bivariate meta-analysis","volume":"12","author":"Muoio","year":"2022","journal-title":"Diagnostics"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.15350","article-title":"Prostate\u2010specific membrane antigen expression in the vasculature of primary lung carcinomas associates with faster metastatic dissemination to the brain","volume":"24","author":"Tanjore Ramanathan","year":"2020","journal-title":"J Cell Mol Medi"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101616","article-title":"The clinical application of 68Ga-PSMA PET\/CT and regulating mechanism of PSMA expression in patients with brain metastases of lung cancer","volume":"28","author":"Pei","year":"2023","journal-title":"Transl Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/apm.12195","article-title":"Prostate\u2010specific membrane antigen expression in tumor\u2010associated vasculature of breast cancers","volume":"122","author":"Wernicke","year":"2014","journal-title":"APMIS"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-018-9878-x","article-title":"Prostate-specific membrane antigen (PSMA) expression in breast cancer and its metastases","volume":"34","author":"Kasoha","year":"2017","journal-title":"Clin Exp Metastasis"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2867-14-26","article-title":"Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases","volume":"14","author":"Nomura","year":"2014","journal-title":"Cancer Cell Int"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.794759","article-title":"Head-to-head comparison of 68Ga-PSMA-11 and 131I in the follow-up of well-differentiated metastatic thyroid cancer: A new potential theragnostic agent","volume":"12","author":"Pitalua-Cortes","year":"2021","journal-title":"Front Endocrinol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000001148","article-title":"PSMA expression in papillary thyroid carcinoma: Opening a new horizon in management of thyroid cancer","volume":"41","author":"Taywade","year":"2016","journal-title":"Clin Nucl Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13550-024-01148-9","article-title":"Potential application of [18F]AlF-PSMA-11 PET\/CT in radioiodine refractory thyroid carcinoma","volume":"14","author":"Van Den Broeck","year":"2024","journal-title":"EJNMMI Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1553505","article-title":"PSMA-targeted PET imaging for brain metastases from non-prostatic solid tumors: A systematic review","volume":"15","author":"Dall\u2019 Armellina","year":"2025","journal-title":"Front Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdad015","article-title":"Epidemiological trends, prognostic factors, and survival outcomes of synchronous brain metastases from 2015 to 2019: a population-based study","volume":"5","author":"Parker","year":"2023","journal-title":"Neuro-Oncology Adv"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1186\/s12885-025-15222-5","article-title":"A large scale multi-dataset investigation of brain metastases distribution based on primary cancer type","volume":"25","author":"Lyu","year":"2025","journal-title":"BMC Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-023-04355-x","article-title":"Identification of incidental brain tumors in prostate cancer patients via PSMA PET\/CT","volume":"163","author":"McLaughlin","year":"2023","journal-title":"J Neuro-Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2024.111711","article-title":"PSMA PET improves characterization of dural-based intracranial lesions in patients with metastatic prostate cancer","volume":"180","author":"Yadav","year":"2024","journal-title":"Eur J Radiol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1111\/jon.12856","article-title":"PET\/CT using68 Ga\u2010PSMA\u2010617 versus18 F\u2010fluorodeoxyglucose to differentiate low\u2010 and high\u2010grade gliomas","volume":"31","author":"Liu","year":"2021","journal-title":"J Neuroimaging"},{"key":"B55","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s12672-026-04434-1","article-title":"PSMA\/PET-guided stereotactic radiosurgery treatment for intracranial metastases from prostate cancer","volume":"17","author":"Goulenko","year":"2026","journal-title":"Discov Onc"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17183088","article-title":"Can PSMA-targeting radiopharmaceuticals be useful for detecting brain metastasis of various tumors using positron emission tomography","volume":"17","author":"Arslan","year":"2025","journal-title":"Cancers"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2020.109199","article-title":"68Ga PSMA PET\/MR in the differentiation of low and high grade gliomas: Is 68Ga PSMA PET\/MRI useful to detect brain gliomas","volume":"130","author":"Akgun","year":"2020","journal-title":"Eur J Radiol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.2174\/1574892818666230519150401","article-title":"PSMA PET\/MR is a new imaging option for identifying glioma recurrence and predicting prognosis","volume":"19","author":"Xiong","year":"2024","journal-title":"PRA"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000002806","article-title":"68Ga\u2013Prostate-Specific Membrane Antigen-11 PET\/CT: A new imaging option for recurrent glioblastoma multiforme","volume":"45","author":"Kunikowska","year":"2020","journal-title":"Clin Nucl Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242216208","article-title":"Comparison between [68Ga]Ga-PSMA-617 and [18F]FET PET as imaging biomarkers in adult recurrent glioblastoma","volume":"24","author":"Brighi","year":"2023","journal-title":"IJMS"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12051202","article-title":"The use of 18F-FET-PET-MRI in neuro-oncology: The best of both worlds\u2014a narrative review","volume":"12","author":"Van De Weijer","year":"2022","journal-title":"Diagnostics"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.2174\/0929867325666171123202644","article-title":"Recent developments of 18F-FET PET in neuro-oncology","volume":"25","author":"Muoio","year":"2018","journal-title":"CMC"},{"key":"B63","doi-asserted-by":"publisher","first-page":"8","DOI":"10.2174\/187652970120501008","article-title":"Usefulness of 11C-methionine positron emission tomography in differential diagnosis between recurrent tumours and radiation necro-sis in patients with glioma: An overview","volume":"5","author":"Vittoria Mattoli","year":"2012","journal-title":"TONEUROSJ"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105068","article-title":"Potential of PSMA-targeting radioligand therapy for Malignant primary and secondary brain tumours using super-selective intra-arterial administration: A single centre, open label, non-randomised prospective imaging study","volume":"102","author":"Pruis","year":"2024","journal-title":"eBioMedicine"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15020364","article-title":"The role of PET imaging in the differential diagnosis between radiation necrosis and recurrent disease in irradiated adult-type diffuse gliomas: A systematic review","volume":"15","author":"Ninatti","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000003820","article-title":"68Ga-PSMA PET\/CT to distinguish brain metastasis of renal cell carcinoma from radiation necrosis after stereotactic radiosurgery","volume":"46","author":"Filizoglu","year":"2021","journal-title":"Clin Nucl Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.269175","article-title":"Symptomatic prostate-specific membrane antigen PET\u2013positive radionecrosis after multimodality brain metastasis\u2013directed treatment including [177 Lu]Lu-PSMA-617","volume":"66","author":"Imber","year":"2025","journal-title":"J Nucl Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000005904","article-title":"Excellent response of glioblastoma multiforme to [177Lu] Lu-PSMA therapy","volume":"51","author":"Ghaedian","year":"2026","journal-title":"Clin Nucl Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000003142","article-title":"177Lu-\/68Ga-PSMA theranostics in recurrent glioblastoma multiforme: Proof of concept","volume":"45","author":"Kumar","year":"2020","journal-title":"Clin Nucl Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000004612","article-title":"Short-interval, low-dose [177Lu]Lu\u2013prostate-specific membrane antigen in the treatment of refractory glioblastoma","volume":"48","author":"More","year":"2023","journal-title":"Clin Nucl Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-04715-z","article-title":"Tumor uptake in glioblastoma multiforme after IV injection of [177Lu]Lu-PSMA-617","volume":"47","author":"Kunikowska","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264850","article-title":"[177 Lu]Lu-PSMA therapy as an individual treatment approach for patients with high-grade glioma: Dosimetry results and critical statement","volume":"64","author":"Graef","year":"2023","journal-title":"J Nucl Med"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.17037","article-title":"Systematic review of the first 40 cases of 177 Lu-PSMA therapy in the treatment of non-prostatic cancer","volume":"44","author":"Golan","year":"2024","journal-title":"Anticancer Res"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.34490","article-title":"Antibody-drug conjugates in prostate cancer: A systematic review","volume":"15","author":"Sardinha","year":"2023","journal-title":"Cureus"},{"key":"B75","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1200\/JCO.2016.34.15_suppl.2065","article-title":"PSMA ADC for progressive glioblastoma: Phase II Brown University Oncology Research Group Study","volume":"34","author":"Elinzano","year":"2016","journal-title":"JCO"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nov206.18","article-title":"ATCT-18: Phase II study of mipsagargin (G-202), a PSMA-activated prodrug targeting the tumor endothelium, in adult patients with recurrent or progressive glioblastoma","volume":"17","author":"Piccioni","year":"2015","journal-title":"Neuro Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.7150\/thno.29884","article-title":"Therapeutic effects of human monoclonal PSMA antibody-mediated TRIM24 siRNA delivery in PSMA-positive castration-resistant prostate cancer","volume":"9","author":"Shi","year":"2019","journal-title":"Theranostics"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol Ther"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2020.06.014","article-title":"PSMA-directed CAR T cells combined with low-dose docetaxel treatment induce tumor regression in a prostate cancer xenograft model","volume":"18","author":"Alzubi","year":"2020","journal-title":"Mol Ther Oncolytics"},{"key":"B80","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1200\/JCO.2022.40.6_suppl.098","article-title":"Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"40","author":"Slovin","year":"2022","journal-title":"JCO"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: A phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14235983","article-title":"Efficacy, safety, and challenges of CAR T-cells in the treatment of solid tumors","volume":"14","author":"Chen","year":"2022","journal-title":"Cancers"},{"key":"B83","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1186\/s12967-025-06523-1","article-title":"Preliminary exploration of PSMA CAR-T combined with GD2 CAR-T for the treatment of refractory\/relapsed gliomas","volume":"23","author":"Gu","year":"2025","journal-title":"J Transl Med"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2020.10.023","article-title":"PSMA-targeted nanoparticles for specific penetration of blood-brain tumor barrier and combined therapy of brain metastases","volume":"329","author":"Ni","year":"2021","journal-title":"J Controlled Release"},{"key":"B85","doi-asserted-by":"publisher","first-page":"128ra39","DOI":"10.1126\/scitranslmed.3003651","article-title":"Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile","volume":"4","author":"Hrkach","year":"2012","journal-title":"Sci Transl Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.3c00159","article-title":"Targeting prostate cancer using bispecific T-cell engagers against prostate-specific membrane antigen","volume":"6","author":"Das","year":"2023","journal-title":"ACS Pharmacol Transl Sci"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2024.129712","article-title":"A PSMA-targeted doxorubicin small-molecule drug conjugate","volume":"104","author":"Yoon","year":"2024","journal-title":"Bioorg Med Chem Lett"},{"key":"B88","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13550-024-01156-9","article-title":"All that glitters is not gold: High uptake on PSMA PET in non-prostate cancers does not mean that treatment with [177Lu]Lu-PSMA-radioligand will be successful","volume":"14","author":"Bogsrud","year":"2024","journal-title":"EJNMMI Res"},{"key":"B89","doi-asserted-by":"publisher","first-page":"3957","DOI":"10.1038\/s41467-025-58452-8","article-title":"Investigative needle core biopsies support multimodal deep-data generation in glioblastoma","volume":"16","author":"Yu","year":"2025","journal-title":"Nat Commun"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2023.106882","article-title":"Automatic segmentation of prostate cancer metastases in PSMA PET\/CT images using deep neural networks with weighted batch-wise dice loss","volume":"158","author":"Xu","year":"2023","journal-title":"Comput Biol Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30098-1","article-title":"Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: A multicentre, retrospective study","volume":"20","author":"Kickingereder","year":"2019","journal-title":"Lancet Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.23736\/S1824-4785.25.03640-4","article-title":"The value of artificial intelligence in PSMA PET: A pathway to improved efficiency and results","volume":"69","author":"Dadgar","year":"2025","journal-title":"Q J Nucl Med Mol Imaging"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1934007\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:05:39Z","timestamp":1788865539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1934007\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":92,"alternative-id":["10.3389\/fonc.2026.1934007"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1934007","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"article-number":"1934007"}}